oxymorphone patch m eets phase 1 end points, page-43

Pixie, when the deal comes, it will be the largest single bio deal in Australian history, and large even by global standards. It will surpass the Acrux deal.

There is no underestimating the money spinner this will be. I once posted what I thought was a very conservative evaluation of the money involved and concluded that it could support a share price of $4 minimum and more optimistically $8 a share based on annual revenues of $200 million earned from a major penetration of the $3 billion oxycodone market alone. Go global and you enhance that.

Add in oxymorphone and topical oxycodone and you could tack on another 50% to my estimates.

Never fear, when this eventually all comes together, our persistence and patience will be rewarded handsomely.